The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-bmd-can-be-surrogate-endpoint-osteoporosis-trials-2025a100102r?src=rss
Author :
Publish date : 2025-12-23 09:35:00
Copyright for syndicated content belongs to the linked Source.
